Prognostic impact of INK4A deletion in Ewing sarcoma

Cancer

Volumn 89, Issue 4, 2000, Pages 793-799

  Wei, Guo ^a   Antonescu, Cristina R ^b   De Alava, Enrique ^c   Leung, Denis ^b   Huvos, Andrew G ^b   Meyers, Paul A ^b   Healey, John H ^b   Ladanyi, Marc ^b  

^a Cangzhou People's Hospital   (China)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Bone tumor; CDKN2A; Cell cycle regulator; p16; Translocation

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA PROBE; EWING SARCOMA; FEMALE; FOLLOW UP; GENE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE DELETION; GENE FREQUENCY; HUMANS; MALE; PROGNOSIS; SARCOMA, EWING'S; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0034663338     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M     Document Type: Article

References (43)

1. The Ewing family of tumors - A subgroup of small-round-cell tumors defined by specific chimeric transcripts
2. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ets-family transcription factor, ERG
3. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma
4. Progress in the molecular biology of Ewing tumors
5. Small round blue cell tumors in bone: Prognostic factors correlated to Ewing's sarcoma and neuroectodermal tumors
6. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities
7. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma
8. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?
9. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma
10. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma
11. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours
12. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors
13. Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization
14. Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma
15. Prognostic impact of deletions at Ip36 and numerical aberrations in Ewing tumors
16. Cytogenetic aberrations in Ewing sarcoma: Are secondary changes associated with clinical outcome?
17. P53 mutations in human tumors with chimeric EWS/FLI-1 genes
18. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas
19. Overexpression of p53 protein in primary Ewing's sarcoma of bone: Relationship to tumour stage, response and prognosis
20. Prognostic impact of P53 status in Ewing sarcoma
21. The INK4A/ARF locus and its two gene products
22. The concept of tumor cell survival factors to explain discrepant p53 mutation frequencies in primary Ewing tumors versus cell lines
23. Is neum-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis?
24. Comparison of soft tissue Ewing's sarcoma and peripheral neuroectodermal tumor
25. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults
26. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
27. The human NOTCH1, 2, and 3 genes are located at chromosome positions 9q34, 1p13-p11, and 19p13.2-p13.1 in regions of neoplasia-associated translocation
28. MDM2 and CDK4 gene amplification in Ewing's sarcoma
29. The INK4a tumor suppressor gene product, p16(Λ(rf)), interacts with MDM2 and neutralizes MDM2's inhibition of p53
30. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF
31. A cell cycle regulator potentially involved in genesis of many tumor types
32. Genomic Alterations of the p 19(ARF) encoding exons in T-cell acute lymphoblastic leukemia
33. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated
34. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas. Relationship to amplification and mRNA levels of CDK4 and CCND1
35. Alterations of the p15, p16, and p18 genes in osteosarcoma
36. CDK4 gene amplification in osteosarcoma: Reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons
37. Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel
38. Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: Implications for therapy
39. Chromosomes in Ewing's sarcoma. ii. nonrandom additional changes, trisomy 8 and der (16)t(1;16)
40. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations
41. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p55 gene mutations
42. Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications